Metformin dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Metformin is a cheap, very safe diabetes drug that many people take hoping to live longer. Big studies in people have not shown it helps with ageing. It also takes the edge off the muscle and fitness you gain from training.
Evidence grade for Metformin: Moderate. The rule: at least one finished study in people, and at least 100 people who took it. The sum on this page: 3 completed trials, 489 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 489
- Human studies
- 3
- Found nothing
- 0
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
FDA approved for type 2 diabetes since 1994. Not approved for ageing or longevity.
6 effects reported, 4 unwanted, 2 wanted, by people using it, not a trial
Goal pages: Fat loss and metabolism, Muscle and strength, Ageing and longevity, Immune system and inflammation
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Metformin is a diabetes pill that lowers blood sugar. Tens of millions of people take it, and it has sixty years of safety data. Some people take it to slow ageing. It is approved for diabetes. It is not approved for ageing.
What people take it for
- Living longer.
- Lower cancer risk.
- Blood sugar control when they are not diabetic.
- A 2014 study that said diabetics on it outlived healthy people.
What studies in people showed
Keep the people and the mice apart. People first. The longest human data is 21 years of follow up in a prevention study. It found no difference in deaths, cancer, heart deaths, heart events, or frailty. The famous claim comes from a 2014 study. It said diabetics on metformin outlived people without diabetes. Two later groups tried to repeat it. Both found the opposite. Then the part that matters if you lift. 94 adults over 65 did 14 weeks of weight training. The dummy pill group gained more muscle than the metformin group. 53 older adults did 12 weeks of cardio. Metformin cut the fitness and insulin gains from training. The trial built to test it for ageing in 3,000 people has still not started. Now mice. A 2013 study in one strain of mice found they lived longer. That study built the whole reputation. Then the US government ran it again, in mixed breed mice at three sites. Those mice did not live longer, male or female.
What people report
Reports, not study results
The good
- The extended release version is much easier on the stomach.
- It is cheap and every doctor knows it.
The bad
- Diarrhoea and stomach pain, mostly in the first weeks.
- Lower vitamin B12 over time. This is a known effect of the drug, not a rumour, and people get it tested.
- Smaller gains from training. Two trials found this in older adults.
- People argue about skipping it on training days. No trial has tested that, so it is a guess.
Where these come from: The training results are from two trials with a dummy pill group. The stomach, B12 and skip-day reports are from longevity forums, r/longevity and clinic write-ups. Those are self-report, not trial results.
My bottom line
Muscle is the number one thing that decides how your second half goes, and this drug got in the way of building it in two trials. If you are not diabetic, I would not take it.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Metformin has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Blood sugar and insulin3,629 people · 4 studies
- Living longer3,576 people · 4 studies
- Keeping or building muscle94 people · 1 study
- Cancer and tumours3,234 people · 1 study
What people using it report
Real people telling you what happened to them. Nobody checked it, and the people who post are not a fair sample, so it cannot prove anything works. It is still the best guide on this page to what people actually do with Metformin, what they expect, and what goes wrong. The full account, including the negative reports, is below.
31 of the 36 indexed goals have no study of any kind behind Metformin
No study in people, animals or cells on this page reports a result for these. That does not prove Metformin does nothing for them. It does mean anything you have heard about Metformin and one of these did not come from a study cited here.
Show full evidence
What is Metformin?
Metformin is a cheap, very safe diabetes drug that many people take hoping to live longer. Big studies in people have not shown it helps with ageing. It also takes the edge off the muscle and fitness you gain from training.
Metformin is a first-choice diabetes drug. Tens of millions of people take it, and there are sixty years of safety data behind it. In the longest study, 3,234 adults at high risk of diabetes were followed for a median of 21 years. Metformin did not cut deaths from any cause, from cancer or from heart disease. It also did not cut cancer cases, major heart events or frailty. In people who train, it took the edge off the gains. 94 adults over 65 who lifted weights for 14 weeks built less muscle on metformin than on a dummy pill. Its name as an anti-ageing drug comes mainly from one 2014 study of medical records. It reported that people taking it outlived people without diabetes. Two later tries to repeat that, in Denmark and in Wales, found the opposite. In mice, the US government's ageing test program, which runs the same test at three sites, found metformin did not really extend life in males or females. None of this makes metformin a bad diabetes drug. It is a very good one. But the case for taking it to slow ageing has not been made, and the study built to test that has still not started.
How does Metformin work?
It blocks part of the energy machinery in mitochondria, called complex I, and switches on AMPK, a fuel sensor. That makes the liver release less sugar and helps the body respond to insulin. The AMPK story is not the whole answer. Research groups still argue over how much comes from complex I, from another enzyme called mitochondrial glycerophosphate dehydrogenase, and from effects in the gut.
What have studies in people found about Metformin?
Huge for diabetes, almost none for ageing. Tens of millions of people have taken metformin, and it has been tested against dummy pills for decades. Almost none of those studies asked whether it slows ageing.
- Decades of studies in diabetes and prediabetes show metformin controls blood sugar and slows the move to diabetes. None of them was built to test ageing.
- Two later tries to repeat the 2014 survival claim, in Danish records and in 20 years of Welsh records covering 129,140 people on metformin, found metformin users dying sooner than matched people without diabetes.
- DPP and DPPOS: 3,234 adults at high risk of diabetes, followed for a median of 21 years. Neither metformin nor a lifestyle program cut deaths from any cause, from cancer or from heart disease.
- UKPDS 34: 342 overweight adults with new type 2 diabetes on metformin, against 411 on the usual diet plan, followed for a median of 10.7 years. Deaths from any cause were 36 percent lower on metformin. That is a diabetes study, not an ageing study.
- MASTERS: 94 adults over 65 lifted weights for 14 weeks. The people on a dummy pill built more muscle than the people on metformin.
- Konopka and colleagues: 53 older adults did 12 weeks of cardio. Metformin shrank their gains in fitness and in how well their bodies handled insulin.
- TAME, the study built to test metformin for ageing in 3,000 adults aged 65 to 79, was not registered on ClinicalTrials.gov as of September 2026. We searched the registry ourselves rather than relying on reports.
What this does not tell you: Everything above is about people with diabetes or prediabetes, or short training studies in healthy older adults. No study has tested whether metformin helps healthy people live longer or stay healthy longer. Those are the people most keen to take it for that.
What do people who took Metformin report?
This is what real people say happened to them, good and bad. Nobody measured it. A report cannot tell a real effect from the lift people get just from expecting it to work, from a diet or training change made at the same time, or from what was really in the vial. We still put it near the top. It is the next best thing to a study in people: what happens when real people use it, including what goes wrong.
- Stomach problems lead the early reports, mainly diarrhoea and belly discomfort. The slow-release form is widely described as easier to take.
- Low vitamin B12 comes up a lot. It is a known effect of the drug, not a myth, and community plans often suggest regular testing.
- People often debate skipping metformin on training days because of the exercise studies. No study has tested that, so it is a guess, not a plan with evidence behind it.
Sources: Longevity forums, r/longevity and clinic write-ups. Uncontrolled self-report, included for what to expect and watch for, not as evidence of effect.
The state of the research
Metformin is the clearest case on this site of a reputation built on record-watching studies that did not hold up. The 2014 study said metformin users outlived matched people without diabetes. It was striking enough to launch the modern debate about drugs for ageing. But it had several built-in biases, and they all pushed the same way. One was a quirk in how follow-up time was counted. Another was dropping people from the count when their treatment was stepped up. A third was a comparison group picked in a way that favoured the drug. Two separate tries to repeat it, one using Danish national records and twins and one following Welsh records for 20 years, found survival running the other way.
The mouse record is also weaker than its reputation. A 2013 study in one strain of mice reported better health and a longer life, and that is where the reputation started. The US government's ageing test program uses mixed-breed mice at three sites, to catch results that do not hold up. There, metformin alone did not really extend life in males or females. Metformin plus rapamycin is often called a success. But the program's own paper says the extra benefit in males did not pass the test set out in advance. It only passed in a different, unplanned analysis, against rapamycin mice from earlier runs rather than the same run.
None of this makes metformin dangerous or useless. It is a good diabetes drug with a long safety record. It does mean that a person taking it to slow ageing is acting on a guess, not a finding, and the study built to test that guess has not begun.
The evidence, in charts
Fig. 1a · how many people
3,723people, across 4 studies in people cited here
| Study | People | Share |
|---|---|---|
| Diabetes Care 2021 | 3,234 | 87% |
| Lancet 1998 | 342 | 9% |
| Aging Cell 2019 | 94 | 3% |
| Aging Cell 2019 | 53 | 1% |
One study holds 87% of these people, so the total rests more on one study than its size suggests. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 3 more studies in people give no headcount and are not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
7 of 8 sources here are studies in people. The rest is not.
- Study in people · done in people788%
- Animal study · done in animals113%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 7 different years, 1998 to 2023, counted from the list of sources on this page.
Fig. 3 · legal status at a glance
US
Approved
UK
Prescription
AU
Prescription
CA
Prescription
Approved in 1 of 4, by prescription in 3, not approved in 0. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 5 · what the molecule is
- Kind of compound
- Small molecule
- Molecule weight
- 129.2 Da (165.6 Da as hydrochloride)
- Half-life
- About 6.5 hoursMedium, 6 to 24 hours
- Chain length
- None on file
Half-life as stated on file: 4 to 9 hours (plasma), longer in erythrocytes
No amino acid sequence is on file for Metformin, which is expected: a small molecule is not built from amino acids.
The studies we cite
- Study in people2019Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: the MASTERS trial
Metformin got in the way of the muscle that lifting weights is meant to build. 94 adults aged 65 and over trained with weights for 14 weeks under supervision. Half took metformin every day, half took a dummy pill. The dummy group put on more lean weight and more thigh muscle, and their thigh muscle came out denser. Strength gains leaned the same way without being clear cut. So the drug did not block the training, it took the edge off it.
94 adults aged 65 and over did 14 weeks of supervised resistance training on 1,700 mg/day metformin or placebo. Placebo gained more lean body mass (p = .003) and thigh muscle mass (p < .001), with greater gains in thigh muscle area (p = .005) and density (p = .020), plus a trend toward blunted strength gains.
- Study in people2019Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults
Metformin dulled the gains from exercise again, this time from cardio. 53 adults with an average age of 62 did 12 weeks of aerobic training, on either metformin or a dummy pill. The people on metformin improved less in fitness, and less in how well their bodies handled blood sugar. Training still helped them. It just helped them less than it helped everyone else.
53 adults averaging 62 years did 12 weeks of aerobic training on metformin or placebo, double-blinded. Metformin diminished the training-induced improvements in insulin sensitivity and cardiorespiratory fitness.
- Study in people2014Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls
This is where the claim that metformin users outlive healthy people came from, and later work points the other way. Nobody was given anything here. Researchers looked back at people already prescribed metformin or an older diabetes pill and compared them with matched people who did not have diabetes. Teams using Danish registry records, twin data and a 20 year Welsh group have since found survival running in the opposite direction. Comparing people who were already taking a drug cannot show the drug caused anything.
The origin of the claim that metformin users outlive non-diabetics. Later replication attempts in Danish registry and twin data, and in a 20 year Welsh cohort, found survival pointing in the opposite direction.
- Study in people1998Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
This is the diabetes study that made metformin a first-choice drug, not a longevity study. 342 overweight adults with new type 2 diabetes took metformin, and 411 stayed on diet as the main plan. They were followed for a median of 10.7 years. Deaths from any cause were 36 percent lower on metformin. A second part of the paper added metformin to the top dose of a sulphonylurea pill, and it pointed the other way on diabetes deaths. Nobody here was a healthy adult taking it to age slower.
UKPDS 34. 342 overweight adults with newly diagnosed type 2 diabetes randomised to metformin versus 411 on conventional diet policy, median 10.7 years. All-cause mortality risk reduction 36% (95% CI 9 to 55). A supplementary randomisation adding metformin to maximum sulphonylurea found a higher risk of diabetes-related death. Not a trial in people without diabetes.
- Study in people2022Reassessing the evidence of a survival advantage in Type 2 diabetes treated with metformin compared with controls without diabetes: a retrospective cohort study
The Danish try at repeating the 2014 survival claim found the opposite. People who started metformin for type 2 diabetes died more often than matched people without diabetes, including inside twin pairs. After other factors were counted, the extra risk was still there. Comparing people who already have diabetes with people who do not cannot show that the drug lengthens life.
Danish registry analysis, 1996 to 2012. Incident metformin monotherapy versus no diabetes was associated with higher mortality in singletons (adjusted IRR 1.32, 95% CI 1.16 to 1.50) and in discordant twins (adjusted IRR 1.64, 95% CI 1.10 to 2.46).
- Study in people2023Comparison of long-term effects of metformin on longevity between people with type 2 diabetes and matched non-diabetic controls
Twenty years of Welsh records tell the same story. 129140 people on metformin for type 2 diabetes did not outlive matched people without diabetes. An early bump in the first three years reversed after five. A short window can manufacture a longevity claim that a long window erases.
Welsh SAIL records. 129,140 metformin-treated type 2 diabetes patients versus matched non-diabetic controls. Over a twenty-year window metformin patients had shorter survival than controls. An apparent benefit in the first three years reversed after five.
- Study in people2021Effect of metformin and lifestyle interventions on mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study
The longest follow-up in people we have found no drop in deaths. 3234 adults at high risk of diabetes were given metformin, an intensive lifestyle program, or a dummy pill. After a median 21 years, 453 had died. Neither metformin nor lifestyle cut deaths from any cause, cancer or heart disease. Preventing diabetes and preventing death were different questions, and only the first one moved.
DPP and DPPOS. 3,234 adults at high risk for type 2 diabetes, median 21 years. 453 deaths. Neither metformin nor lifestyle reduced all-cause, cancer or cardiovascular mortality.
- Animal study2013Metformin improves healthspan and lifespan in mice
In mice: a 2013 study in one strain of mice found metformin improved health and lifespan. The US government's multi-site ageing test program, using mixed-breed mice, did not find a real lifespan gain in males or females.
The positive mouse result that launched metformin's longevity reputation, in C57BL/6 mice. The multi-site Interventions Testing Program, using genetically heterogeneous mice specifically to catch results that do not travel, did not reproduce a significant lifespan effect in either sex.
Common questions
Has Metformin been tested in people?
Yes. 489 people given it across 3 completed trials cited here, 0 of which found nothing. Metformin is a cheap, very safe diabetes drug that many people take hoping to live longer. Big studies in people have not shown it helps with ageing. It also takes the edge off the muscle and fitness you gain from training.
What is the Metformin dosage?
Approved medicine. No human dose established for unlabelled uses. Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose. FDA approved for type 2 diabetes since 1994. Not approved for ageing or longevity.
Is Metformin FDA-approved?
FDA approved for type 2 diabetes since 1994. Not approved for ageing or longevity.
Does metformin extend lifespan?
There is no evidence from studies in people that it does. In mice, a 2013 study reported better health and a longer life, and that built the drug's name. But the US government's ageing test program, which runs mixed-breed mice at three sites to catch results that do not repeat, found no real lifespan gain in males or females.
Should I take metformin if I lift weights?
Two studies in older adults found metformin cut the benefit of training. With weights, people gained less lean mass and thigh muscle. With cardio, they gained less fitness and less improvement in how they handled insulin. If you take it for diabetes, talk with your doctor about a drug you need. If you take it for longevity while also training, those two goals seem to work against each other.
What about the study showing metformin users outlive people without diabetes?
That 2014 study of medical records is where metformin's longevity name comes from. Two later tries to repeat it, using Danish records and twins and 20 years of Welsh records, found the opposite. The original also has several biases that all favour metformin.
Has the TAME trial started?
No. TAME is the study built to test metformin for ageing in 3,000 older adults. As of September 2026 it is not registered on ClinicalTrials.gov, about ten years after its design was published. It has had money to plan but not money to run.
Latest reading on Metformin
Blog posts about Metformin, newest first.